Duration of antibiotic therapy for pediatric ventilator‐associated pneumonia
- 1 January 2025
- journal article
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70262
Abstract
Background: Although a seven‐day course of antibiotic therapy for ventilator‐associated pneumonia (VAP) is recommended for adult patients, the optimal duration in children remains unclear. Our study described the management of pediatric VAP by focusing on the treatment and clinical outcomes. Methods: We performed a retrospective cohort study in the Pediatric Intensive Care Unit (PICU) of a tertiary children's hospital. Children under 18 diagnosed with VAP between April 2016 and June 2023 were included. VAP was defined by the Centers for Disease Control and Prevention of the United States criteria. Exclusion criteria included co‐infections or a lack of prior antibiotic therapy. Demographic and microbiological data were collected from medical records. Results: Ninety patients were eligible for enrollment. The median age was 19 months (IQR: 10–69 months) and 44% were girls. The median pediatric index of mortality‐2 score was 4 (IQR: 1.3–8.6). Staphylococcus aureus was the most frequently isolated pathogen (28%), followed by Pseudomonas aeruginosa (22%). The median length of antibiotic therapy was six days (IQR: 6–7 days). Mortality on days 7 and 28 was 1% ( n = 1) and 6% ( n = 5), without VAP‐related deaths. The recurrence rate was 10% ( n = 9). The median ventilation‐free and PICU‐free days at day 28 were 22 and 17, respectively. Conclusion: Most patients received a six to seven‐day course of antibiotic therapy without adverse outcomes. The recurrence rate and the ventilation‐free and PICU‐free days were equivalent to or better than those reported previously for adults.Keywords
This publication has 22 references indexed in Scilit:
- Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trialseClinicalMedicine, 2023
- Healthcare-Associated Infections2022
- Less Is More? Antibiotic Treatment Duration inPseudomonas aeruginosaVentilator-Associated PneumoniaClinical Infectious Diseases, 2022
- Correction to: Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trialIntensive Care Medicine, 2022
- Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 UpdateInfection Control & Hospital Epidemiology, 2022
- Effect of Gram Stain–Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated PneumoniaJAMA Network Open, 2022
- Assessment of the accuracy and consistency in the application of standardized surveillance definitions: A summary of the American Journal of Infection Control and National Healthcare Safety Network case studies, 2010-2016American Journal of Infection Control, 2017
- National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004American Journal of Infection Control, 2004
- Comparison of 8 vs 15 Days of Antibiotic Therapy for Ventilator-Associated Pneumonia in AdultsJAMA, 2003
- PIM2: a revised version of the Paediatric Index of MortalityIntensive Care Medicine, 2003